ARS Pharmaceuticals to show new analyses and partner late-breakers on neffy at AAAAI 2026

ARS Pharmaceuticals, Inc. announced that five poster presentations, one healthcare professional (HCP) case report, plus two late breakers from partners at ALK-Abelló A/S (ALK) centered on neffy, will be featured at the 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting, February 27 to March 2, 2026 in Philadelphia, Pennsylvania.

The posters highlight health-economic analyses, patient preference research, usability and pharmacokinetic comparisons evaluating neffy relative to injectable epinephrine products.

The complete list of presentations and meeting activities is below. Abstracts can be viewed at annualmeeting.aaaai.org. Attendees are encouraged to visit the ARS Pharma booth #737, view the poster presentations at the Convention Center, Level 2, Hall E, and attend a Non-CME Problem Based Learning Presentation: Reimagining Epinephrine Administration with Epinephrine Nasal Spray, to learn more about neffy.

View the full list of presentations HERE.

About neffy® is a nasal spray used for emergency treatment of allergic reactions including anaphylaxis, in adults and children aged 4 years and older who weigh 33 lbs. or greater.